Endpoints News

HHS can move forward with firing 2,000 probationary workers after an appeals court paused a lower ruling — but the legal fight is far from over.

Biotech M&A has stalled — no $1B+ deals since January. IPOs are quiet, PIPEs are down 75%, and XBI has dropped 24% YTD. Startups are conserving cash to survive.

Pharma CEOs warn €100B in EU R&D and capital investment is at risk, as companies eye a U.S. shift amid Trump tariffs. Industry pushes for swift policy change.

Trump says pharma tariffs are coming “very shortly” to push drugmakers out of China. AstraZeneca and GSK stocks fell 6% and 5.5% after the remarks.

Q&A: Lundbeck’s head of R&D Johan Luthman on neuroscience strategy, the $2.6B seizure drug buyout, and what the BMS–Karuna deal means for Cobenfy.

In a Phase 2b trial, Cartesian’s CAR-T therapy led 33% of myasthenia gravis patients to reach minimal symptoms at 12 months; 83% showed sustained clinical response.

A $15B federal boost is needed to maintain the U.S. biotech edge, a new report warns, as proposed Trump-era research cuts threaten to cede ground to China’s fast-growing innovation engine.

Exclusive: Merida Biosciences launches with $121M Series A to develop treatments for autoimmune and allergic diseases, starting with Graves’ disease and food allergy.

FDA’s rare disease hub continues after staff cuts, with just one departure, director Amy Comstock Rick says — though broader agency changes will still affect its work.

RayThera hauls in $110M Series A to advance three anti-inflammatory drug candidates, with its lead program set to enter Phase 1.